Salvage lymph node dissection for metastatic castration resistant prostate adenocarcinoma

@#Presented here is a 66 year old male who is a known case of prostate adenocarcinoma gleason score 9 (4+5) and who underwent open radical retropubic prostatectomy with bilateral pelvic lymph node dissection, followed by 45 cycles of radiation therapy with continous androgen deprivation therapy. Afer completion of radication therapy, Choline PET CT was done which revealed enlarged paracaval, aortocaval and paraaortic lymph nodes. The patient then underwent exploratory laparotomy, retroperitoneal lymph node dissection which found four out of twenty five lymph nodes removed that were positive for tumor metastases. There was a significant drop in the prostate specific antigen level two months post-surgery, from 7.43 to 1.54. Androgen deprivation therapy was still continued post-operatively.

Rol de la cirugía en cáncer de próstata oligometastásico / Surgery in Oligometastatic Prostate Cancer

Es indudable que el cáncer de próstata es objeto de permanente investigación dada su alta prevalencia y morbimortalidad asociada. Sin embargo, el cáncer oligometastásico reconocido como una entidad aparte, es un tópico ha ido ganando interés durante los últimos años. Se ha propuesto que el cáncer oligometastásico podría ser considerado una etapa previa al cáncer metastásico avanzado, dada su evolución más indolente, permitiendo plantear nuevos cursos de tratamiento y nuevos enfrentamientos terapéuticos, que los utilizados en etapas más complejas. En este trabajo se realizó una revisión no-sistemática de la literatura actual respecto al rol de la cirugía en el cáncer oligometastásico, para esto se utilizaron las bases de datos Pubmed y MGH Treadwell Library, con limites dentro de los últimos 10 años además de publicaciones en las revistas Journal of Urology y European Urology. Se revisaron bases de datos chilenas reportadas en Datos Estadísticos e Información en Salud (DEIS). Históricamente, el tratamiento estándar para cáncer de próstata metastásico ha sido el tratamiento paliativo a largo plazo con terapia de deprivación de andrógenos (ADT). Sin embargo, basado en el comportamiento particular que presentaría el cáncer de próstata oligometastásico, se han realizado estudios en los que la cirugía cada vez juega un rol más protagónico. Los nuevos datos son altamente sugerentes que la cirugía podría representar una modalidad terapéutica útil en el manejo de cáncer de próstata oligometastásico. Sin embargo, aún es necesario definir protocolos respecto al manejo de esta entidad y se requieren mayores estudios para definir cuál sería la mejor forma de lograr resultados o si presentaría beneficio asociar el manejo quirúrgico a otras terapias complementarias. AU

There is no doubt that prostate cancer is subject of permanent research because of its high prevalence and associated morbidity and mortality. However, oligometastatic cancer as a particular entity, is a topic that has been gaining interest over the past few years. It has been proposed that oligometastatic cancer could be considered a stage prior to advanced metastatic cancer, given its more indolent course, allowing to consider if there would be benefits in new therapeutic approaches than those used in more advanced stages. In this paper, we performed a non-systematic review of the current literature regarding the role of surgery in oligometastatic cancer, using Pubmed and MGH Treadwell Library databases with limits within the last 10 years. And also, publications in journals as "European Urology" and "Journal of Urology". Chilean databases reported in "Datos Estadísticos e Información en Salud" (DEIS) were reviewed. Historically, the standard treatment for metastatic prostate cancer has been long-term palliative treatment with androgen deprivation therapy (ADT). However, based on the particular behavior of oligometastatic prostate cancer, studies have been performed in which surgical treatment is playing a more prominent role. The new data is highly suggestive that surgery could represent a useful therapeutic modality in the management of prostate cancer. However, it is still necessary to define protocols regarding the management of this entity and more studies are required to achieve this and define what would be the best way to accomplish results or whether it would be beneficial to associate surgical management with other complementary therapies.AU

Rationale of Surgery in Locally Advanced and Oligometastatic Prostate Cancer

There is no clear consensus for the best treatment of men with locally advanced prostate cancer. As a first step, radiation therapy or primary hormone therapy or radical prostatectomy with extended pelvic lymph node dissection is used. But it seems impossible to have a good oncologic result with single treatment modality. Traditionally, external beam radiation therapy with adjuvant hormone therapy is most preferred treatment method in locally advanced prostate cancer and radical prostatectomy has not been routinely used because of high rates of margin positive and lymph node metastasis. But, recently published articles showed that surgery in multimodal setting is effective treatment modality and not inferior to radiation therapy in oncologic outcomes. Perioperative morbidities of surgery and incontinence rates are similar to surgery of organ confined diseases, and patients with primary radiotherapy seem to have high rate of lower urinary tract symptoms and radiation related complications compared with radical prostatectomy with adjuvant radiotherapy. There is still controversy in regard to performing surgery for locally advanced prostate cancer. We review the studies with surgery in locally advanced prostate cancer and compare with radiation therapy in multimodal setting, and review the studies with surgery in oligometastatic prostate cancer.